TMX Newsfile·2026-03-12 21:41Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that during the Class Period, Corcept's defendants misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval [5]. - Defendants communicated confidence in the NDA submission and indicated no anticipated obstacles to approval, despite the FDA raising concerns about the clinical evidence [5]. - The lawsuit claims that when the true situation regarding the NDA was revealed, investors suffered damages due to the misrepresentation [5].